Neil MacDonald1. 1. Gerald Bronfman Centre, Montreal, Quebec, Canada.
Abstract
PURPOSE OF REVIEW: This article reviews the current status of the definition of cancer cachexia, and comments on future initiatives to refine it and to use it as a foundation for a cancer cachexia classification system. RECENT FINDINGS: There has been a plethora of work by expert panels defining cachexia. Stemming from this work, an expert panel has published a definition of cancer cachexia and a three level staging system: precachexia, cachexia, and refractory cachexia. Colleagues in the cancer pain field have put forward a sophisticated pain classification system. Work to develop a similar classification system for cachexia is now commencing. Aside from improved communication, these efforts may also enable the oncology community to better appreciate the importance of cancer cachexia and to participate in interdisciplinary treatment programmes to combat cachexia. SUMMARY: The quest to determine the pathophysiology of cancer cachexia and to use this knowledge to identify patient subsets will further research. Equally important, the fruits of this endeavour will lead to a higher priority for addressing cachexia with consequent development of a multimodal approach to management.
PURPOSE OF REVIEW: This article reviews the current status of the definition of cancer cachexia, and comments on future initiatives to refine it and to use it as a foundation for a cancer cachexia classification system. RECENT FINDINGS: There has been a plethora of work by expert panels defining cachexia. Stemming from this work, an expert panel has published a definition of cancer cachexia and a three level staging system: precachexia, cachexia, and refractory cachexia. Colleagues in the cancer pain field have put forward a sophisticated pain classification system. Work to develop a similar classification system for cachexia is now commencing. Aside from improved communication, these efforts may also enable the oncology community to better appreciate the importance of cancer cachexia and to participate in interdisciplinary treatment programmes to combat cachexia. SUMMARY: The quest to determine the pathophysiology of cancer cachexia and to use this knowledge to identify patient subsets will further research. Equally important, the fruits of this endeavour will lead to a higher priority for addressing cachexia with consequent development of a multimodal approach to management.
Authors: Barry J Laird; Donald C McMillan; Peter Fayers; Kenneth Fearon; Stein Kaasa; Marie T Fallon; Pål Klepstad Journal: Oncologist Date: 2013-08-21
Authors: Claribel Simmons; Donald C McMillan; Sharon Tuck; Cat Graham; Alistair McKeown; Mike Bennett; Claire O'Neill; Andrew Wilcock; Caroline Usborne; Kenneth C Fearon; Marie Fallon; Barry J Laird Journal: Oncologist Date: 2019-04-11
Authors: Derek Grose; Graham Devereux; Louise Brown; Richard Jones; Dave Sharma; Colin Selby; David S Morrison; Kirsty Docherty; David McIntosh; Penny McElhinney; Marianne Nicolson; Donald C McMillan; Robert Milroy Journal: Lung Cancer Int Date: 2014-03-05